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Objective: To characterize and compare primary and restenotic lesions of the superficial femoral artery and analyze the
contribution of TGF-/Smad3 signaling to the pathophysiology of peripheral artery occlusive disease.
Methods and Results: Immunohistochemical studies were performed on specimens retrieved from the superficial femoral
artery of patients undergoing either atherectomy for primary atherosclerotic or recurrent disease after stenting and/or
prior angioplasty. Immunohistochemical analysis revealed a significantly higher smooth muscle cell (SMC) content
(-actin) and expression of Smad3 in restenotic lesions while primary lesions contained significantly more leukocytes
(CD45) and macrophages (CD68). Further studies demonstrated colocalization of Smad3 with -actin and PCNA,
suggesting a role for Smad3 in the proliferation observed in restenotic lesions. To confirm a role for Smad3 in SMC
proliferation, we both upregulated Smad3 via adenoviral mediated gene transfer (AdSmad3) and inhibited Smad3
through transfection with siRNA in human aortic SMCs, then assessed cell proliferation with tritiated thymidine.
Overexpression of Smad3 enhanced whereas inhibition of Smad3 decreased cell proliferation.
Conclusion: Differences in cellular composition and cell proliferation in conjunction with the finding that Smad3 is
expressed exclusively in restenotic disease suggest that TGF-, through Smad3 signaling, may play an essential role in
SMC proliferation and the pathophysiology of restenosis in humans. (J Vasc Surg 2009;49:1289-95.)
Clinical Relevance. Intimal hyperplasia leading to restenosis significantly limits the long-term success of percutaneous
interventions for lower extremity vascular occlusive disease. Because the mechanisms leading to the development of
restenosis are likely different from those that produce primary atherosclerosis, a comparison of the pathophysiology of
restenotic vs primary atherosclerotic plaque will enable us to better define the cellular events that lead to recurrent disease.
This will enable us to develop targeted therapies for the prevention of restenosis following vascular intervention for the
treatment of peripheral arterial disease.Intimal hyperplasia leading to restenosis significantly
limits the long-term success of percutaneous interventions
for lower extremity vascular occlusive disease. It has been
reported that in patients undergoing superficial femoral
artery (SFA) revascularization, restenosis occurs within 6
months in one-fourth of patients who receive stents and
nearly one-half of those who receive angioplasty alone.1
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doi:10.1016/j.jvs.2008.11.096This equates to over 50% of patients requiring reinterven-
tion following angioplasty of the SFA.2 It has been sug-
gested that the mechanisms leading to the development of
restenosis may be different from those that produce pri-
mary atherosclerosis. The growing use of endovascular
atherectomy in peripheral vascular disease provides the
opportunity to compare the pathophysiology of restenotic
vs primary atherosclerotic plaque and to better define the
cellular events that lead to recurrent disease following
vascular intervention.
Primary atherosclerotic plaque has been shown to be
hypocellular, consisting primarily of ambiguous ground
substance and collagen with a variable lipid component.3 In
contrast, restenotic lesions are typically hypercellular with
foci of vascular smooth muscle cells (SMCs) and extracel-
lular matrix.4 Vascular SMC proliferation has been impli-
cated in the pathogenesis of intimal hyperplasia and ulti-
mately restensosis,5-9 and has been studied in both primary
atheromata and restenotic lesions. The majority of these
studies have been conducted in specimens derived from
coronary arteries. Moreover, the data vary widely; in some
studies there was little evidence of cellular proliferation in
restenotic lesions10-13 and in others, proliferation was a
prominent feature of this process.14,15 It has been sug-
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coronary artery disease. However, the composition of ath-
erosclerosis or intimal hyperplasia in peripheral arterial or
superficial femoral artery disease has not been well charac-
terized.
Among the many growth factors implicated in the
development of intimal hyperplasia, transforming growth
factor- (TGF-), specifically TGF-1, has been well estab-
lished as a primary contributor to this process. TGF-1
expression is increased in injured and restenotic vessels and
in neointimal hyperplasia after balloon injury in ani-
mals.8,10,16,17 Furthermore, exposure of arteries to exoge-
nous TGF-1 after injury results in increased neointima
formation in animal models.7 Although it has been shown
that TGF- signals through several pathways, it is believed
that the main signaling mechanism is through the Smad
family of proteins. TGF- signals by binding to type I
receptors followed by formation of a heteromeric complex
with the type II receptor resulting in phosphorylation and
activation of the TGF- downstream signaling molecules
Smad2 and Smad3. Activated Smad2 or Smad3 then het-
erodimerize with Smad4 and the resulting complex trans-
locates to the nucleus where it acts as a transcription factor
to regulate the expression of target genes.18 Interestingly,
our previous work in an animal model of restenosis revealed
that Smad3 is upregulated in injured arteries and that in the
rat model of intimal hyperplasia, increased levels of Smad3
are associated with increased SMC proliferation. Based on
these previous findings, we hypothesized that the mecha-
nism behind the formation of restenotic vs primary athero-
sclerotic plaque is different and that expression of the
TGF- signaling protein Smad3 may in part be responsible
for these differences.
In the current study, we demonstrate that the patho-
physiology of the restenotic lesion is distinct from that of
primary atheromatous plaque in the superficial femoral
artery. Furthermore, we demonstrate that these differences
may be related to changes in Smad3 expression and SMC
proliferation. Together, our findings contribute to a broader
understanding of the pathophysiology of peripheral artery
restenosis in humans.
MATERIALS AND METHODS
General methods. Cell culture reagents were from
Gibco Invitrogen Cell Culture (Carlsbad, Calif). Chemi-
cals, if not specified, were purchased from Sigma Chemical
Company (St Louis, Mo).
Human atherectomy specimens. Specimens were re-
trieved from the superficial femoral artery of patients un-
dergoing percutaneous atherectomy for primary athero-
sclerotic lesions (n  5) or restenotic lesions after stenting
and/or prior angioplasty (n  3). All specimens were
collected under the approval of the Institutional Review
Board. Cores of tissue in no specific orientation were ob-
tained from percutaneous atherectomy procedures using
the Silver Hawk atherectomy device (ev3 Inc., Plymouth,
Minn). Between four to six tissue cores were paraffin em-
bedded into one block, then cut into 7m sections. Foreach patient sample, at least three sections, through multi-
ple tissue cores, were analyzed that were separated by over
100 m.
Immunohistochemistry. Paraffin embedded tissues
were cut into 7 m sections for analysis. Quantitative immu-
nohistochemistry using mouse anti-PCNA 1:50 (Santa Cruz
Biotechnology, SantaCruz,Calif),mouse anti--actin 1:800
(Sigma Aldrich, St Louis, Mo), mouse anti-CD68 1:50
(Dako, Carpinteria, Calif), mouse anti-CD45 1:50 (Dako),
and rabbit anti-Smad3 1:50 (Invitrogen, Carlsbad, Calif)
was performed as described elsewhere.19 Staining was com-
pared with the appropriate negative controls using rabbit or
mouse IgG at a concentration (in g/mL) equal to that of
the diluted antibody. Staining was visualized with a Nikon
(Melville, NY) Eclipse E800 uprightmicroscope and digital
images were acquired using a RetigaEXi CCD digital cam-
era. Percent positivity was calculated as (number of positive
cells/number of total nuclei) per section by identifying
positive cells (brown) vs hematoxylin stained cells by pixel
color on Adobe Photoshop (Version 9.0.2, San Jose, Calif),
then counting each subset of cells on NIH image software
(ImageJ 1.36b, Bethesda, Md).
Immunofluorescent staining was performed with don-
key anti-mouse Alexa 555 or donkey anti-rabbit Alexa 488
(Molecular Probes, Invitrogen, Carlsbad, Calif). TO-PRO
3 (Molecular Probes) was used to identify nuclei. Fluores-
cent staining was visualized and digital images were taken
on a Zeiss LSM 510 laser scanning confocal imaging system
(Zeiss, Thornwood, NY) with the appropriate argon beam
lasers. For each specimen, cells were counted in four fields
at882 magnification. Digital images were analyzed using
Zeiss image browser software.
Smoothmuscle cell culture. Smoothmuscle cells and
media were purchased from ScienCell (San Diego, Calif)
and maintained at 37°C with 5% CO2.
Smad3 siRNA. The sequence for the human Smad3
gene was obtained from the Pubmed Nucleotide database.
Using the BLOCK-iT RNAi Designer (Invitrogen), poten-
tial siRNA sequences were generated. Two sequences were
ultimately tested for their ability to inhibit Smad3 expres-
sion by both Western blot and reverse transcriptase poly-
merase chain reaction (PCR). The sequence used for the
following experiments was 5=-GCUCCAUCUCCUAC-
UACGAGCUGAA-3=.
Proliferation assay. Primary human aortic smooth
muscle cells (HAoSMC) (passages 2-6) were infected with
either AdLacZ or AdSmad3 (3  104 particles/cell in 2%
FBS for 4 hours). Following overnight recovery in 2% FBS
and 48 hours of serum starvation (in 0.5% FBS), tritiated
thymidine incorporation, as a surrogate for DNA synthesis,
was assessed as previously described.20
Primary HAoSMCs (P2-6), were transfected with either
siRNA to Smad3 or a scramble control (20 pmoles/well in
a 24-well plate). Following 48 hours of serum starvation (in
0.5% FBS), tritiated thymidine incorporation was assessed
as previously described.20
Apoptosis assay. Vascular SMCs were infected with
AdLacZ or AdSmad3 as described above. After 48 hours of
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 5 Edlin et al 1291serum starvation, cells were lysed. The lysate was then
subjected to apoptosis ELISA (Roche, Indianapolis, Ind)
following manufacturer’s instruction.
Statistical analysis. Values were expressed as means
SE. Unpaired Student t test was used to evaluate the
statistical differences between control and treated groups.
Multiple comparisons were made using ANOVA and
Dunn’s post-hoc correction. Values of P  .05 were con-
sidered significant. All experiments were repeated at least
three times.
RESULTS
Characterization of atherosclerotic lesions. Samples
Fig 1. Immunohistochemical analysis of human ather
primary atherosclerotic (n  5) and restenotic lesions
(A) -actin, (B) PCNA, (C) CD68, and (D) CD45. Mag
ing in restenotic or primary atherosclerotic lesions expre
.001 restenotic compared with primary lesions).were collected from the superficial femoral artery of pa-tients undergoing atherectomy for primary atherosclerotic
or restenotic lesions. Immunohistochemical analysis re-
vealed a significantly higher expression of -actin (a marker
for SMCs) and PCNA (a marker for proliferating cells) in
restenotic lesions compared with primary atherosclerotic
lesions (Fig 1, A, B, and E). In contrast, primary lesions
expressed significantly more inflammatory cell markers
CD68 (macrophages) and CD45 (leukocytes) (Fig 1,C, D,
and E). Thus, cell proliferation appears to be a major
feature of human restenotic lesions. Furthermore, rest-
enotic lesions are comprised primarily of SMCs, whereas
primary atheromata contain significantly more inflamma-
tory cells. Consistent with prior reports, we also found that
otic and restenotic lesions. Immunohistochemistry of
3). Representative sections are shown. Staining for
ation400. E, Quantification of positive immunostain-
as a ratio of positive/total cells  standard error (*P oscler
(n 
nific
ssedrestenotic plaques were overall more cellular than primary
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lesions vs 222 35 cells/hpf for primary lesions, P .05).
Smad3 expression and localization. These observa-
tions prompted us to explore the mechanism responsible
for differences between primary and restenotic lesions.
Studies have shown that TGF- is a ubiquitous cytokine
associated with restenotic plaque. Moreover, we have pre-
viously shown that the TGF- signaling molecule Smad3 is
upregulated after carotid balloon arterial injury in the rat.
We therefore explored whether theremight be a differential
in Smad3 expression in human primary and restenotic
atherectomy samples. We found that Smad3 was expressed
exclusively in restenotic lesions (Fig 2). Whereas 25.9% 
2.6% of cells in restenotic lesions were Smad3 positive,
no primary atherosclerotic plaque cells were identified as
expressing Smad3. Immunohistochemistry data from all
five primary atherosclerotic plaques and three restenotic
plaques have been included in Supplement 1.
We next attempted to localize the Smad3 expression in
restenotic plaque by double immunostaining of Smad3
with either -actin (Fig 3,A) or PCNA (Fig 3, B), followed
by visualization with confocal microscopy. We found that
all visualized Smad3 cells were -actin positive (nuclear
Smad3, green, is surrounded by cytoplasmic -actin, red)
(Fig 3, A), suggesting that enhanced Smad3 expression is
confined to SMCs. We also found that that all Smad3 cells
were PCNA positive (nuclear Smad3, green, and nuclear
PCNA, red, merge to depict yellow nuclei) (Fig. 3, B).
Thus, Smad3 is exclusively associated with proliferating
SMCs within restenotic lesions.
The effect of Smad3 on human SMC proliferation
in vitro. Our in vivo findings suggest a role for Smad3 in
mediating the increased cell proliferation observed in human
restenotic lesions. To further test this hypothesis, Smad3
was overexpressed in human aortic SMCs (HAoSMCs) via
Fig 2. Smad3 staining of human atherosclerotic and restenotic
lesions. Smad3 staining of primary atherosclerotic lesions (n  5)
and restenotic lesions (n  3). Representative sections are shown.
Magnification 400.adenovirus mediated gene transfer (AdSmad3) while con-trol cells were infected with a control virus (AdLacZ) (Fig.
4,A). After 48 hours, DNA synthesis was measured using a
tritiated thymidine incorporation assay. Consistent with
our in vivo findings, upregulation of Smad3 resulted in a
significant increase in cell proliferation compared with the
AdLacZ control (Fig 4, B). To confirm that this observa-
tion is due to overexpression of Smad3 rather than
changes in TGF- receptor expression, as has been pre-
viously reported by McCaffrey et al16, we have shown by
Western blotting in Supplement 2 that infection with
either AdSmad3 or AdLacZ does not affect levels of
TGF- receptors type I and II. To further define the role
of Smad3 in cell proliferation, Smad3 expression in
HAoSMCs was downregulated using an siRNA (Fig 4,
A). As shown in Fig. 4, B, downregulation of Smad3 resulted
in a significant decrease in cell proliferation compared with a
scramble-treated HAoSMC control, further substantiating
the importance of Smad3 in human SMC proliferation.
The role of Smad3 expression in vascular SMC
apoptosis. We next asked the question whether Smad3
overexpression had any effect on vascular SMC apoptosis.
Since we had already shown that restenotic plaques, which
Fig 3. Colocalization of Smad3 with -actin and PCNA. Double
immunofluorescent staining of restenotic plaque. A, Staining re-
veals (a) nuclei (blue), (b) nuclear Smad3 (green), (c) -actin (red),
and (d) colocalization (nuclear green surrounded by cytoplasmic
red) (white arrows). B, Staining reveals (a) nuclei (blue), (b)
nuclear Smad3 (green), (c) nuclear PCNA (red), and (d) colocal-
ization (yellow) (white arrows).overexpressed Smad3, were more cellular than primary
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sion may be associated with decreased SMC apoptosis.
However, as demonstrated in Fig 5, although the level of
apoptosis in cells overexpressing Smad3 was significantly
higher than the negative control and cells infected with
AdLacZ, it is still very low and several fold lower than the
Fig 4. The effect of Smad3 on human SMC proliferation. A, West-
ern blotting of human aortic SMCs demonstrating the effects of
Smad3 overexpression via AdSmad3 infection and Smad3 down-
regulation via transient transfection with Smad3 siRNA. B, 3H-
thymidine incorporation in human aortic SMCs following overex-
pression or inhibition of Smad3 (n 3, *P .001 compared with
AdLacZ or scrambled control).
Fig 5. The effect of Smad3 on SMC apoptosis. Vascular SMCs
were infected with AdLacZ or AdSmad3, then lysed and analyses
for apoptosis using ELISA. *P  .05 compared with negative
control.positive control. This therefore suggested that Smad3 ex-pression does not play a major role in regulation of apopto-
sis in vitro.
DISCUSSION
We have found that there is significantly more cell
proliferation in restenotic plaque compared with primary
atheromata in patients with lower extremity vascular dis-
ease. In addition, restenotic plaque is comprised primarily
of SMCs whereas atheromata contain significantly more
inflammatory cells. These differences in cellular composi-
tion and cell proliferation in conjunction with the novel
finding that Smad3 is expressed exclusively in restenotic
disease suggest that Smad3 expressionmay play a role in the
mechanism underlying restenotic, as opposed to primary
atherosclerotic disease.
It was surprising that we found almost no white blood
cells (WBCs) in restenotic plaque, since WBCs and inflam-
mation have been shown to play an integral role in the
genesis of atherosclerosis. However, our own immunohis-
tochemical analysis of rat carotid arteries after balloon
angioplasty also revealed very few neointimal inflammatory
cells, as evidenced by immunohistochemical staining for
CD45 and CD68. Moreover, our observations are sup-
ported by similar findings in other animal models of intimal
hyperplasia.21,22 This differential localization ofWBCs pre-
dominately in primary but not restenotic lesions highlights
another distinction between these two processes. Whereas
the inflammatory response is critically important in athero-
sclerosis, inflammation does not appear to be as essential in
the development of restenosis.
While there is a wealth of data regarding the character-
ization of atherectomy specimens derived from coronary
arteries,10-15,23 there has been only a limited evaluation of
peripheral lesions and specifically cell proliferation in pe-
ripheral lesions. In several studies, rates of apoptosis in
peripheral vs central restenotic lesions have been de-
scribed.3,24 Others have pooled peripheral and central
atherectomy specimens for the characterization of rest-
enotic vs primary atherosclersosis.14,25,26 Recently, studies
with drug-coated stents have implied that the pathophysi-
ology of restenotic disease in coronary vs peripheral vascu-
lar disease is quite distinct. Stents coated with rapamycin
significantly inhibit restenosis in the coronary circulation
whereas rapamycin coated stents were not successful in
diminishing the rate of restenosis when used in the periph-
eral circulation.27 These findings underscore the impor-
tance of studying the pathophysiology of restenosis specif-
ically in the peripheral arterial system.
SMC proliferation has been identified as an invariable co-
mponent of intimal hyperplasia in animals, but previous stud-
ies have yielded conflicting results regarding the frequency of
cell proliferation in human restenotic lesions.10-15,23 Picker-
ing et al reported a significantly higher percentage of pro-
liferating cells in restenotic as opposed to primary athero-
sclerotic plaque (59% vs 20%).14 Our findings support
those of Pickering in that we identified that almost 70% of
cells in restenotic lesions were PCNA positive whereas
slightly over 20% of cells in primary atherosclerotic lesions
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eration is a more dominant process in peripheral vs coro-
nary restenotic lesions. Skowasch et al were unable to
identify proliferation in restenotic coronary lesions.13
Moreover, Glover et al found proliferation in only one of
twenty coronary restenotic samples as measured by in situ
hybridization for histone 3mRNA expression.11O’Brien et
al found PCNA positivity in 26% of restenotic coronary
lesions, but in each of these restenotic lesions, less than 1%
of cells were actually PCNA.10 Similarly, Marek et al
found only 1% to 3% of cells expressed PCNA in 41% of
restenotic carotid lesions.12 Alternatively, we have found a
proliferative index of near 70% in restenotic lesions re-
moved from the superficial femoral artery. Schwartz et al
hypothesized that restenosis is characterized by prolifera-
tion only in the early phase of its development; thus lesions
derived from human coronary arteries if they are sampled at
a later stage of their development, are not typified by
proliferation.26 Our data, however, do not support this
hypothesis since all of our peripheral restenotic specimens
were taken at a point greater than 6 months following the
initial intervention and as previously noted, proliferation in
these lesions was still quite robust.
Having identified proliferating SMCs in the restenotic
lesion, we next focused on potential signaling mechanisms
that might account for increased proliferation. It is well
established that TGF- ligands are upregulated following
vascular injury.28We have previously shown in a rat balloon
injury model that the TGF- signaling molecule Smad3 is
also upregulated after vascular injury. Furthermore, over-
expression of Smad3 was associated with increased SMC
proliferation in our animal model. This is a surprising
finding since TGF- activity is traditionally thought to be
associated with inhibition of SMC proliferation. In fact, our
previous work suggests that while TGF- can inhibit SMC
proliferation through a non-Smad3 pathway, in the pres-
ence of high levels of Smad3, which develop after arterial
injury, TGF- appears to have the converse effect of stim-
ulating SMC proliferation. Our new and similar findings in
human vessels and cells serve to confirm this hypothesis and
make Smad3 a relevant target in the treatment of human
restenotic disease.
There is conflicting data regarding the role of Smad3 in
intimal hyperplasia. Kobayashi et al have previously shown
that SMCs derived from a Smad3 knockout mouse (ie, cells
that are lacking Smad3) have increased baseline prolifera-
tion compared with wild type cells.17 These findings would
imply that Smad3 is involved in endogenous suppression of
SMC proliferation. Mimicking this experimental situation
we inhibited Smad3 expression with siRNA and found an
opposite result: inhibition of SMC proliferation. The expla-
nation for the discrepancy between ours and Kobayashi’s
findings is not entirely clear.
In addition to stimulation of cell proliferation, elevated
levels of Smad3 may induce other processes that lead to
intimal hyperplasia. Extracellular matrix production has
been shown to be an important component of intimal
hyperplasia, and we have previously shown that Smad3 isessential for vascular SMC production of fibronectin.29
Alternatively, Smad3 may influence SMC apoptosis. How-
ever, our in vitro data suggest that the effect of Smad3 may
be minimal. Finally, overexpression of Smad3 may stimu-
late SMC migration, another process that has been shown
to play a role in the development of intimal hyperplasia.
This would be one area for future in vitro studies.
One of the limitations of current study is the use of
human aortic SMCs for in vitro studies. As the aortic bed
does not clinically succumb to occlusive lesions compared
with the SFA, it is possible that SMCs from these two
different regions may have distinct responses to intracel-
lular levels of Smad3. Another limitation is the small
number of patient samples included. However, our find-
ings even with an n of 3 were quite dramatic and all of
our findings were statistically different, suggesting that
Smad3-mediated SMC proliferation could be an impor-
tant mechanism unique to restenosis.
The present study confirms that the mechanism under-
lying the development of primary atherosclerotic plaque in
the superficial femoral artery is quite distinct from that of
restenotic disease. White blood cells contribute signifi-
cantly to primary plaque while restenotic lesions are highly
cellular, comprised primarily of SMCs; in addition, SMC
proliferation is quite robust. Moreover, the TGF- signal-
ing protein Smad3 is upregulated in restenotic lesions and
cellular localization studies suggest that this might account
for the highly proliferative nature of these lesions. A better
understanding of the relationship between Smad3 and cell
proliferation will provide us with further insight into the
mechanisms by which TGF- induces intimal hyperplasia as
well as enable us to target specific aspects of this signaling
mechanism for therapy to prevent restenosis after treatment
of peripheral arterial disease.
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